W E Wysokinski1, K P Cohoon2, R M Melduni2, M Mazur2, N Ammash2, T Munger2, E Konik2, T McLeod3, Izabeal Gosk-Bierska2, R D McBane2. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States of America. Electronic address: wysokinski.waldemar@mayo.edu. 2. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States of America. 3. General Internal Medicine, Department of Medicine, Mayo Clinic Rochester, MN, United States of America.
Abstract
BACKGROUND: P-selectin - a biomarker of platelet and endothelial cell activation is elevated in patients with non-valvular atrial fibrillation (NVAF). However, the association between sP-selectin level and thromboembolic complications in NVAF patients remains controversial. We tested the hypothesis that plasma soluble P-selectin (sPSL) level correlates with the measures of left atrial blood stasis in NVAF. METHODS: Plasma sPSL concentration was measured using solid-phase ELISA in 103 NVAF patients (age 63 ± 14 years; 26% women) and 48 normal sinus rhythm controls (NSR; age 64 ± 14 years; 41% women) who were not on aspirin. Within the group of NVAF cases, 27 had no spontaneous echocardiographic contrast (SEC) detected by transesophageal echocardiography, 31had mild SEC, 15 moderate, 20 severe, and 10 patients had left atrial appendage thrombus (LAAT). RESULTS: The median soluble sPSL level was higher in NVAF cases compared to NSR controls [(interquartile range) 26 (20-32) ng/mL vs 22 (15-29) ng/mL, p = 0.0045]. Only NVAF patients with CHA2DS2-VASc score ≥ 1 had higher sPSL level compared to NSR controls. Patients with severe SEC had significantly higher sPSL levels [32 (24-38) ng/mL] compared to all other NVAF patients (p = 0.0042) and to NSR controls (p < 0.0001). Also NVAF patients with LAAT had higher sPSL level compared to NSR controls. CONCLUSIONS: There is a direct correlation between p-selectin level and severe blood stasis in the left atrium. Only NVAF patients with CHA2DS2-VASc score ≥ 1 or with LAAT had higher sPSL level compared to NSR controls.
BACKGROUND:P-selectin - a biomarker of platelet and endothelial cell activation is elevated in patients with non-valvular atrial fibrillation (NVAF). However, the association between sP-selectin level and thromboembolic complications in NVAFpatients remains controversial. We tested the hypothesis that plasma soluble P-selectin (sPSL) level correlates with the measures of left atrial blood stasis in NVAF. METHODS: Plasma sPSL concentration was measured using solid-phase ELISA in 103 NVAFpatients (age 63 ± 14 years; 26% women) and 48 normal sinus rhythm controls (NSR; age 64 ± 14 years; 41% women) who were not on aspirin. Within the group of NVAF cases, 27 had no spontaneous echocardiographic contrast (SEC) detected by transesophageal echocardiography, 31had mild SEC, 15 moderate, 20 severe, and 10 patients had left atrial appendage thrombus (LAAT). RESULTS: The median soluble sPSL level was higher in NVAF cases compared to NSR controls [(interquartile range) 26 (20-32) ng/mL vs 22 (15-29) ng/mL, p = 0.0045]. Only NVAFpatients with CHA2DS2-VASc score ≥ 1 had higher sPSL level compared to NSR controls. Patients with severe SEC had significantly higher sPSL levels [32 (24-38) ng/mL] compared to all other NVAFpatients (p = 0.0042) and to NSR controls (p < 0.0001). Also NVAFpatients with LAAT had higher sPSL level compared to NSR controls. CONCLUSIONS: There is a direct correlation between p-selectin level and severe blood stasis in the left atrium. Only NVAFpatients with CHA2DS2-VASc score ≥ 1 or with LAAT had higher sPSL level compared to NSR controls.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano Journal: Circulation Date: 2006-08-15 Impact factor: 29.690
Authors: M E Goldman; L A Pearce; R G Hart; M Zabalgoitia; R W Asinger; R Safford; J L Halperin Journal: J Am Soc Echocardiogr Date: 1999-12 Impact factor: 5.251
Authors: A L Klein; R A Grimm; R D Murray; C Apperson-Hansen; R W Asinger; I W Black; R Davidoff; R Erbel; J L Halperin; D A Orsinelli; T R Porter; M F Stoddard Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: Raymonda Rastegar; David J Harnick; Peter Weidemann; Valentin Fuster; Barry Coller; Juan J Badimon; James Chesebro; Martin E Goldman Journal: J Am Coll Cardiol Date: 2003-02-19 Impact factor: 24.094
Authors: Dwayne S G Conway; Lesly A Pearce; Bernard S P Chin; Robert G Hart; Gregory Y H Lip Journal: Circulation Date: 2003-06-09 Impact factor: 29.690
Authors: Jelena Kornej; Petra Büttner; Erik Holzwirth; Tina Fischer-Schaepmann; Danilo Obradovic; Mirjam von Lucadou; Edzard Schwedhelm; Günter Daum; Gerhard Hindricks; Gunther Marsche; Markus Trieb; Holger Thiele Journal: Heart Vessels Date: 2021-08-30 Impact factor: 2.037